Skip to main content
. 2016 Jun 21;7(28):42844–42858. doi: 10.18632/oncotarget.10212

Figure 1. DC101, evofosfamide, and low dose doxorubicin multimodal treatment of KP sarcomas.

Figure 1

A. Tumor volume of KP sarcomas. Groups were treated by intraperitoneal injection of control IgG 20 mg/kg 3 times per week, DC101 20 mg/kg 3 times per week, evofosfamide (Evo) 50 mg/kg 5 times per week, and/or low dose doxorubicin (Dox) 1 mg/kg 3 times per week. Photos B. and graphs C. of PCNA immunohistochemistry for proliferation, TUNEL immunofluorescence for apoptosis, CD31 immunohistochemistry for microvessel density, CD31 and TUNEL immunofluorescence for endothelial cell (EC)-specific apoptosis, and nuclear HIF-1α immunohistochemistry for HIF-1α activity. Bars represent standard deviation. **p < 0.05 compared to all other groups.